Business context and reporting period
This filing is for VPC Impact Acquisition Holdings (VIH), a Cayman Islands blank-check company—not Bakkt, Inc. VIH was formed on July 31, 2020, completed its IPO in September 2020, and had no operating business at December 31, 2020. The audited reporting period is inception through December 31, 2020, not a standalone fourth quarter; the filing provides no Q4-only results or prior-year comparable period.
After year-end, on January 11, 2021, VIH agreed to combine with Bakkt Holdings, LLC. The proposed transaction included a $325 million PIPE and was subject to closing conditions. The 10-K does not present Bakkt’s operating financial results.
Financial metrics
| Metric | Period or date | Reported amount |
|---|---|---|
| Revenue | Inception through Dec. 31, 2020 | No operating revenue |
| Formation and operating costs | Inception through Dec. 31, 2020 | $1,006,862 |
| Trust investment interest | Inception through Dec. 31, 2020 | $4,193 |
| Net loss | Inception through Dec. 31, 2020 | $1,002,669 |
| Operating cash flow | Inception through Dec. 31, 2020 | $(341,800) |
| Cash outside trust | Dec. 31, 2020 | $1,177,678 |
| Cash and investments in trust | Dec. 31, 2020 | $207,376,213 |
| Total assets | Dec. 31, 2020 | $208,788,850 |
| Total liabilities | Dec. 31, 2020 | $8,153,666 |
| Shareholders’ equity | Dec. 31, 2020 | $5,000,004 |
Margins are not meaningful for this pre-combination SPAC. VIH reported no long-term debt or off-balance-sheet financing arrangements. Liabilities included $7,258,021 in deferred underwriting fees, payable only if a business combination is completed. The balance sheet classified $195,635,180 of Class A shares as temporary equity because they were subject to possible redemption.
Changes, outlook and risks
- Comparisons: No prior comparable operating period is available; VIH began operations in 2020 and had no operating revenue.
- Liquidity: Management said available working capital and borrowing capacity were expected to cover needs through the earlier of a business combination or one year from filing. Cash outside the trust was approximately $1.2 million; management noted actual search and transaction costs could exceed estimates.
- Proposed Bakkt transaction: The PIPE investors subscribed for 32.5 million shares for $325 million. The transaction required at least $425 million of available cash after redemptions, before deferred underwriting commissions and transaction expenses. Excess redemptions could prevent closing or require restructuring or additional financing.
- Deadline and redemption: VIH had until September 25, 2022 to complete a business combination. If unsuccessful, it was required to redeem public shares and liquidate; warrants would expire worthless. Public shareholders generally could seek redemption at approximately the trust value per share, subject to the filing’s terms and limitations.
- Other material risks: Risks included transaction failure, COVID-19-related disruption, competition for targets, potential dilution, sponsor and management conflicts, third-party claims against trust funds, and uncertainty around financing. The sponsor’s trust-account indemnity may not be collectible.
- Controls and audit: Management concluded disclosure controls were effective at year-end. The auditor issued an unqualified opinion on the financial statements; it did not audit internal control over financial reporting, and the filing omitted management’s internal-control assessment under the applicable transition provisions.
Most important facts for investors to verify
- Confirm the filing entity: this is VIH’s SPAC 10-K, not Bakkt’s operating-company 10-K; obtain Bakkt’s financial statements and transaction disclosure for business performance.
- Review the final merger documents for closing conditions, redemptions, transaction expenses, the PIPE’s completion, and resulting ownership and dilution.
- Verify available cash at closing against the $425 million minimum and assess any financing needed if redemptions are high.
- Check trust assets, deferred underwriting fees, and any creditor claims that could affect redemption proceeds.
- Evaluate the founder-share conversion and warrant terms, including potential dilution and the possibility that warrants expire worthless.